Pamela Wapnick, Chief Financial Officer at Metagenomi Therapeutics, Inc. (MGX), sold 1,581 shares at $1.60 ($3K) on 2026-03-05, disclosed to the SEC on 2026-03-09.
Open-market sale of $3k MGX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| MGX | SELL | 2025-12-08 | $3K | — | Filing → |
| MGX | SELL | 2025-12-01 | $3K | — | Filing → |
| MGX | SELL | 2025-06-09 | $3K | — | Filing → |